Status:
COMPLETED
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
Lead Sponsor:
Neothetics, Inc
Conditions:
Weight
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
LIPO-102 is under evaluation for treatment of abdominal adiposity
Eligibility Criteria
Inclusion
- 18 - 50 years old inclusive
- Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS
- BMI \< 25kg/m sq
- Stable diet and exercise and body weight
Exclusion
- Prior treatment of abdominal subcutaneous adipose tissue
- Females within 12 months postpardum
- Known hypersensitivity to the drugs or components
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01180465
Start Date
April 1 2010
End Date
September 1 2010
Last Update
March 26 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States
2
New York, New York, United States